Metsera, Inc. (Nasdaq: MTSR) ('Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

Metsera, Inc MTSR IPO will take place January, 31 on the NASDAQ exchange under the ticker MTSR. The company is offering shares at an expected price between $15.00 and $17.00 per share with an insider ...

This article highlights recent developments in healthcare, including the U.S. FDA's approval of Alzheimer's and diabetes ...

Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. Aurion focuses on regenerative therapies, Maze advances precision medicines for ...

Recent health news includes a profit boost for Swedish manufacturer Getinge, a human case of bird flu detected in the UK, and ...

Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering. Read more here.

The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.

Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to ...